Effectiveness of Smoking Cessation Program in a Community Health System
Launched by VIRTUA HEALTH, INC. · Oct 25, 2021
Trial Information
Current as of June 23, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The Cancer Patient Tobacco Questionnaire (C-TUQ) survey tool will be used to address the primary and secondary outcome measures. This tool is publicly available on the National Cancer Institutes Grid-Enabled Measures website and was developed by NCI and the American Association for Cancer Research. This tool is a 22-item self-report survey designed to capture information about tobacco use by cancer patients and cancer survivors. Comparisons will be made for those patients that enroll in the structured smoking cessation program versus those patients that have opted to quit on their own.
Pri...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any Gender
- • Over 18 years of age
- • Able to read and understand English
- • Able to sign the informed consent form
- • A current cigarette smoker defined as smoking within 30 days
- • Diagnosed with cancer and wants to quit smoking
- Exclusion Criteria:
- • • Individuals with Dementia
- • ECOG Performance Status 3-4
- • Survival prognosis less than 12 months
- • Currently participating in a smoking cessation program that is not provided by Virtua
- • Individuals who do not want to quit smoking
- • Pregnant Women
About Virtua Health, Inc.
Virtua Health, Inc. is a leading healthcare organization dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and a robust infrastructure, Virtua Health collaborates with healthcare professionals and researchers to conduct high-quality clinical studies across a variety of therapeutic areas. By prioritizing patient safety and ethical standards, Virtua Health aims to contribute to the advancement of medical knowledge and the development of new treatments that enhance the quality of life for individuals within the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Voorhees, New Jersey, United States
Patients applied
Trial Officials
Theresa Carducci, MSN, RN, CCRP
Principal Investigator
Virtua Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials